Basel, Switzerland-based Roche has started a price war between its hepatitis C drug, Pegasys, and Schering-Plough's Peg-Intron.

FORBES: Schering-Plough's Incredible Shrinking Profits

The on-balance volume (OBV) shows a pattern of higher highs, line c, which confirms the price action.

FORBES: 2 ETFs Riding China's Wave

Below is a three month price history chart comparing the stock performance of C vs.

FORBES: Citigroup Takes Over #187 Spot From Tesoro Corporation